Jazz Pharmaceuticals Beats Q1, Shorts Fold, Street Lifts Targets

Jazz Pharmaceuticals just delivered its strongest quarterly beat in years — and the positioning data shows shorts were already getting out of the way before the numbers hit.

Q1 2026 revenue came in at $1.07 billion, up nearly 19% year-on-year. Net income flipped from a $92.5 million loss to $293.1 million profit. Diluted EPS of $4.43 topped prior-year's loss per share of $1.52 by a wide margin and beat consensus by $1.67. The stock closed at $212.26 on May 5, up 4.1% on the week and 13.5% in the past month — the kind of re-rating that suggests this print resolved a debate that had been building in the market for some time.

The most striking feature in the positioning data is how sharply short interest collapsed in the final week of April. SI % of free float peaked near 12% on April 20–22 and then fell almost three points in a single session on April 23, landing at roughly 9% by late April and holding there into the results. That unwinding — nearly 1.75 million shares covered in a matter of days — looks like pre-earnings short covering rather than a random drift. The ORTEX short score edged back to 53.2 from a brief spike toward 59 in mid-to-late April, confirming the pressure eased ahead of the print. Cost to borrow tells the same story: it ran above 0.45% for most of April before dropping sharply, hitting 0.23% by May 5 — a fall of nearly 47% on the week. Availability is generous, with the borrow pool far from constrained, and the options market was leaning constructively into results with the put/call ratio at 0.51, comfortably below its 20-day average of 0.56. None of these signals point to residual squeeze pressure; the short trade has largely been flushed.

How this article was generated